
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3393984/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	In Vitro Genotoxicity Evaluation of an Antiseptic Formulation Containing Kaolin and Silver Nanoparticles. Nanomaterials, 2022, 12, 914.	4.1	5
2	Genotoxicity of Graphene-Based Materials. Nanomaterials, 2022, 12, 1795.	4.1	8
3	Genotoxicity of 12 Mycotoxins by the SOS/umu Test: Comparison of Liver and Kidney S9 Fraction. Toxins, 2022, 14, 400.	3.4	3
4	Time Course of Renal Transcriptomics after Subchronic Exposure to Ochratoxin A in Fisher Rats. Toxins, 2021, 13, 177.	3.4	2
5	In Vitro Genotoxicity Assessment of Functional Ingredients: Betaine, Choline, and Taurine. Foods, 2021, 10, 339.	4.3	5
6	Oral subchronic exposure to the mycotoxin ochratoxin A induces key pathological features of Parkinson's disease in mice six months after the end of the treatment. Food and Chemical Toxicology, 2021, 152, 112164.	3.6	16
7	Biomonitoring of Mycotoxins in Plasma of Patients with Alzheimer's and Parkinson's Disease. Toxins, 2021, 13, 477.	3.4	8
8	Validation of the in vitro comet assay for DNA cross-links and altered bases detection. Archives of Toxicology, 2021, 95, 2825-2838.	4.2	17
9	In vitro genotoxicity assessment of functional ingredients: DHA, rutin and α-tocopherol. Food and Chemical Toxicology, 2021, 153, 112237.	3.6	9
10	In vitro mutagenicity assessment of fried meat-based food from mass catering companies. Food and Chemical Toxicology, 2021, 156, 112494.	3.6	1
11	Prioritization of Mycotoxins Based on Their Genotoxic Potential with an In Silico-In Vitro Strategy. Toxins, 2021, 13, 734.	3.4	7
12	Genotoxicity evaluation of fried meat: A comprehensive review. Food and Chemical Toxicology, 2020, 136, 110943.	3.6	9
13	European Regulatory Framework and Safety Assessment of Food-Related Bioactive Compounds. Nutrients, 2020, 12, 613.	4.1	35
14	Genotoxicity of Silver Nanoparticles. Nanomaterials, 2020, 10, 251.	4.1	64
15	Novel approach for the detection of alkylated bases using the enzyme-modified comet assay. Toxicology Letters, 2020, 330, 108-117.	0.8	16
16	Applying the comet assay to fresh vs frozen animal solid tissues: A technical approach. Food and Chemical Toxicology, 2019, 132, 110671.	3.6	8
17	Sex-dependent gene expression after ochratoxin A insult in F344 rat kidney. Food and Chemical Toxicology, 2019, 123, 337-348.	3.6	16
18	Standardisation of the in vitro comet assay: influence of lysis time and lysis solution composition on the detection of DNA damage induced by X-rays. Mutagenesis, 2018, 33, 25-30.	2.6	21

#	Article	IF	CITATIONS
19	Structure-activity relationship of new antimalarial 1-aryl-3-susbtituted propanol derivatives: Synthesis, preliminary toxicity profiling, parasite life cycle stage studies, target exploration, and targeted delivery. European Journal of Medicinal Chemistry, 2018, 152, 489-514.	5.5	4
20	Sex differences in ochratoxin a toxicity in F344 rats after 7 and 21 days of daily oral administration. Food and Chemical Toxicology, 2018, 111, 363-373.	3.6	13
21	Novel antimalarial chloroquine- and primaquine-quinoxaline 1,4-di-N-oxide hybrids: Design, synthesis, Plasmodium life cycle stage profile, and preliminary toxicity studies. European Journal of Medicinal Chemistry, 2018, 158, 68-81.	5.5	43
22	Is oxidative stress involved in the sex-dependent response to ochratoxin A renal toxicity?. Food and Chemical Toxicology, 2018, 116, 379-387.	3.6	11
23	In vitro evaluation of the genotoxicity of poly(anhydride) nanoparticles designed for oral drug delivery. International Journal of Pharmaceutics, 2017, 523, 418-426.	5.2	14
24	Evaluation of the cytotoxicity, genotoxicity and mucus permeation capacity of several surface modified poly(anhydride) nanoparticles designed for oral drug delivery. International Journal of Pharmaceutics, 2017, 517, 67-79.	5.2	33
25	Toxicity and biodistribution of orally administered casein nanoparticles. Food and Chemical Toxicology, 2017, 106, 477-486.	3.6	15
26	Database on the taxonomical characterisation and potential toxigenic capacities of microorganisms used for the industrial production of food enzymes and feed additives, which do not have a recommendation for Qualified Presumption of Safety. EFSA Supporting Publications, 2017, 14, 1274E.	0.7	6
27	Genotoxic evaluation of poly(anhydride) nanoparticles in the gastrointestinal tract of mice. International Journal of Pharmaceutics, 2017, 530, 187-194.	5.2	4
28	Unveiling the Metabolic Changes on Muscle Cell Metabolism Underlying p-Phenylenediamine Toxicity. Frontiers in Molecular Biosciences, 2017, 4, 8.	3.5	7
29	Effective protection of mice against Shigella flexneri with a new self-adjuvant multicomponent vaccine. Journal of Medical Microbiology, 2017, 66, 946-958.	1.8	12
30	Purported Interactions of Amyloid-l² andÂGlucocorticoids in Cytotoxicity andÂGenotoxicity: Implications inÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2016, 54, 1085-1094.	2.6	2
31	Toxicological Aspects of Polymer Nanoparticles. , 2016, , 521-550.		1
32	Exploring the scope of new arylamino alcohol derivatives: Synthesis, antimalarial evaluation, toxicological studies, and target exploration. International Journal for Parasitology: Drugs and Drug Resistance, 2016, 6, 184-198.	3.4	16
33	Gene expression kinetics of renal transporters induced by ochratoxin A in male and female F344 rats. Food and Chemical Toxicology, 2016, 98, 169-178.	3.6	10
34	In Vitro and in Vivo Anti-Trypanosoma cruziActivity of New Arylamine Mannich Base-Type Derivatives. Journal of Medicinal Chemistry, 2016, 59, 10929-10945.	6.4	30
35	Mycotoxins as Food Carcinogens. , 2016, , 261-298.		5
36	Non-clinical toxicity studies on bioactive compounds within the framework of nutritional and health claims. International Journal of Food Sciences and Nutrition, 2015, 66, S13-S21.	2.8	3

#	Article	IF	CITATIONS
37	Presence of mycotoxins in animal milk: A review. Food Control, 2015, 53, 163-176.	5.5	189
38	Genotoxicity of Aflatoxin B1 and Ochratoxin A after simultaneous application of the in vivo micronucleus and comet assay. Food and Chemical Toxicology, 2015, 76, 116-124.	3.6	58
39	Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis, 2015, 36, S61-S88.	2.8	149
40	Toxicity evaluation of nanocarriers for the oral delivery of macromolecular drugs. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 206-217.	4.3	21
41	Does the duration of lysis affect the sensitivity of the in vitro alkaline comet assay?. Mutagenesis, 2015, 30, 21-28.	2.6	26
42	Assessment of DNA damage using comet assay in middle-aged overweight/obese subjects after following a hypocaloric diet supplemented with cocoa extract. Mutagenesis, 2015, 30, 139-146.	2.6	18
43	Ochratoxin A kinetics: A review of analytical methods and studies in rat model. Food and Chemical Toxicology, 2014, 72, 273-288.	3.6	34
44	Variation of DNA damage levels in peripheral blood mononuclear cells isolated in different laboratories. Mutagenesis, 2014, 29, 241-249.	2.6	30
45	An ECVAG inter-laboratory validation study of the comet assay: inter-laboratory and intra-laboratory variations of DNA strand breaks and FPG-sensitive sites in human mononuclear cells. Mutagenesis, 2013, 28, 279-286.	2.6	78
46	Levels of ochratoxins in Mediterranean red wines. Food Control, 2013, 32, 63-68.	5.5	34
47	Phenazine N,N′-dioxide scaffold as selective hypoxic cytotoxin pharmacophore. Structural modifications looking for further DNA topoisomerase II-inhibition activity. MedChemComm, 2013, 4, 595.	3.4	14
48	A review on ochratoxin A transcriptomic studies. Food and Chemical Toxicology, 2013, 59, 766-783.	3.6	49
49	Validation of an antiviral assay method for quantifying IFN-α5 activity in macaque and human serum. Bioanalysis, 2013, 5, 289-305.	1.5	1
50	Enhancing the sensitivity of the comet assay as a genotoxicity test, by combining it with bacterial repair enzyme FPG. Mutagenesis, 2013, 28, 271-277.	2.6	74
51	Cytotoxicity and Cell Interaction Studies of Bioadhesive Poly(anhydride) Nanoparticles for Oral Antigen/Drug Delivery. Journal of Biomedical Nanotechnology, 2013, 9, 1891-1903.	1.1	28
52	A Pilot Study of the Nutritional Status of Opiate-Using Pregnant Women on Methadone Maintenance Therapy. Substance Use and Misuse, 2012, 47, 286-295.	1.4	19
53	Toxicity Studies of Poly(Anhydride) Nanoparticles as Carriers for Oral Drug Delivery. Pharmaceutical Research, 2012, 29, 2615-2627.	3.5	24
54	An approach to the toxicity and toxicokinetics of aflatoxin B1 and ochratoxin A after simultaneous oral administration to fasted F344 rats. Food and Chemical Toxicology, 2012, 50, 3440-3446.	3.6	25

#	Article	IF	CITATIONS
55	Inter-laboratory variation in DNA damage using a standard comet assay protocol. Mutagenesis, 2012, 27, 665-672.	2.6	79
56	A polyphenol-enriched cocoa extract reduces free radicals produced by mycotoxins. Food and Chemical Toxicology, 2012, 50, 989-995.	3.6	25
57	Co-occurrence of type-A and type-B trichothecenes in barley from a northern region of Spain. Food Control, 2012, 25, 81-88.	5.5	58
58	OTA-producing fungi in foodstuffs: A review. Food Control, 2012, 26, 259-268.	5.5	90
59	Quantification of ochratoxin A and five analogs in Navarra red wines. Food Control, 2012, 27, 139-145.	5.5	31
60	Co-occurrence of mycotoxins in Spanish barley: A statistical overview. Food Control, 2012, 28, 295-298.	5.5	18
61	Co-occurrence of aflatoxins, ochratoxin A and zearalenone in barley from a northern region of Spain. Food Chemistry, 2012, 132, 35-42.	8.2	56
62	3-Trifluoromethylquinoxaline <i>N</i> , <i>N</i> ′-Dioxides as Anti-Trypanosomatid Agents. Identification of Optimal Anti- <i>T. cruzi</i> Agents and Mechanism of Action Studies. Journal of Medicinal Chemistry, 2011, 54, 3624-3636.	6.4	49
63	Co-occurrence of aflatoxins, ochratoxin A and zearalenone in breakfast cereals from spanish market. Food Control, 2011, 22, 1949-1955.	5.5	78
64	Kidney and liver distribution of ochratoxin A in male and female F344 rats. Food and Chemical Toxicology, 2011, 49, 1935-1942.	3.6	31
65	Ochratoxin A reduces aflatoxin B1 induced DNA damage detected by the comet assay in Hep G2 cells. Food and Chemical Toxicology, 2011, 49, 2883-2889.	3.6	57
66	Validation of a UHPLC-FLD analytical method for the simultaneous quantification of aflatoxin B1 and ochratoxin a in rat plasma, liver and kidney. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2733-2740.	2.3	45
67	Genetic toxicology and preliminary <i>in vivo</i> studies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents. Drug and Chemical Toxicology, 2011, 34, 285-293.	2.3	10
68	Novel Phenazine 5,10-Dioxides Release [•] OH in Simulated Hypoxia and Induce Reduction of Tumour Volume <i>In Vivo</i> . ISRN Pharmacology, 2011, 2011, 1-11.	1.6	12
69	The fullâ€length isoform of the mouse pleckstrin homology domainâ€interacting protein (PHIP) is required for postnatal growth. FEBS Letters, 2010, 584, 4121-4127.	2.8	17
70	DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide. Bioorganic and Medicinal Chemistry, 2010, 18, 3125-3132.	3.0	23
71	Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation. Bioorganic and Medicinal Chemistry, 2010, 18, 4433-4440.	3.0	24
72	Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers. Bioorganic and Medicinal Chemistry, 2010, 18, 5391-5399.	3.0	27

#	Article	IF	CITATIONS
73	Structural modifications on the phenazine N,N′-dioxide-scaffold looking for new selective hypoxic cytotoxins. European Journal of Medicinal Chemistry, 2010, 45, 5362-5369.	5.5	24
74	Occurrence of Ochratoxin A in Southern Spanish Generous Wines under the Denomination of Origin "Jerez-Xérès-Sherry and â€̃Manzanilla' Sanlúcar de Barrameda― Toxins, 2010, 2, 1054-1064.	3.4	14
75	Mutagenic Activity in Meat Samples after Deep-frying in Olive Oil. , 2010, , 989-996.		1
76	Effect of a cocoa polyphenol-enriched extract in cells treated with aflatoxin B1 and ochratoxin A. Toxicology Letters, 2010, 196, S339.	0.8	0
77	Relevance of the gender, age and fasting conditions in ochratoxin A kinetics. Toxicology Letters, 2010, 196, S340.	0.8	1
78	Effects of fasting and gender on ochratoxin A toxicokinetics in F344 rats. Food and Chemical Toxicology, 2010, 48, 3159-3166.	3.6	17
79	Antiproliferative effect of flavomannin-6,6′-dimethylether from Tricholoma equestre on Caco-2 cells. Toxicology, 2009, 264, 192-197.	4.2	10
80	Occurrence of patulin and its dietary intake through apple juice consumption by the Spanish population. Food Chemistry, 2009, 113, 420-423.	8.2	70
81	Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs. Bioorganic and Medicinal Chemistry, 2009, 17, 1623-1629.	3.0	25
82	Negative Evidence for Stachydrine or <i>Galeopsis ladanum</i> L. Seeds as the Causal Agents of Coturnism after Quail Meat Ingestion. Journal of Agricultural and Food Chemistry, 2009, 57, 11055-11059.	5.2	6
83	A different kinetic profile of ochratoxin A in mature male rats. Food and Chemical Toxicology, 2009, 47, 1921-1927.	3.6	32
84	Ochratoxin A decontamination: A review. Food Control, 2009, 20, 326-333.	5.5	176
85	Impact of gender and age on ochratoxin a toxicokinetics in rat. Toxicology Letters, 2009, 189, S142.	0.8	Ο
86	Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. Toxicology Letters, 2009, 190, 140-149.	0.8	31
87	New copper-based complexes with quinoxaline N1,N4-dioxide derivatives, potential antitumoral agents. Journal of Inorganic Biochemistry, 2008, 102, 119-126.	3.5	58
88	Simple high-performance liquid chromatography—fluorescence detection method for plasma, kidney and liver of rat as a tool for toxicology studies. Journal of Chromatography A, 2008, 1215, 100-106.	3.7	19
89	OTA-producing fungi isolated from stored cocoa beans. Letters in Applied Microbiology, 2008, 47, 197-201.	2.2	17
90	Gene expression changes induced by ochratoxin A in renal and hepatic tissues of male F344 rat after oral repeated administration. Toxicology and Applied Pharmacology, 2008, 230, 197-207.	2.8	51

8.2

95

#	Article	IF	CITATIONS
91	Antitumoral Effect of Phenazine <i>N</i> ⁵ , <i>N</i> ¹⁰ -Dioxide Derivatives on Caco-2 Cells. Chemical Research in Toxicology, 2008, 21, 1578-1585.	3.3	25
92	Minimizing creatine kinase variability in rats for neuromuscular research purposes. Laboratory Animals, 2008, 42, 19-25.	1.0	16
93	A Simple Chemical Method Reduces Ochratoxin A in Contaminated Cocoa Shells. Journal of Food Protection, 2008, 71, 1422-1426.	1.7	25
94	Comparative Acute Systemic Toxicity of Several Quinoxaline 1,4-Di-N-oxides in Wistar Rats. Arzneimittelforschung, 2007, 57, 339-346.	0.4	0
95	In-house validation of a high-performance liquid chromatography analytical method for quantification of ochratoxin A in unfermented grape juice. Journal of the Science of Food and Agriculture, 2007, 87, 2164-2169.	3.5	0
96	Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure–activity relationships. Bioorganic and Medicinal Chemistry, 2007, 15, 3356-3367.	3.0	260
97	A quinoxaline 1,4-di-N-oxide derivative induces DNA oxidative damage not attenuated by vitamin C and E treatment. Chemico-Biological Interactions, 2007, 168, 95-105.	4.0	47
98	In vitro gene expression data supporting a DNA non-reactive genotoxic mechanism for ochratoxin A. Toxicology and Applied Pharmacology, 2007, 220, 216-224.	2.8	55
99	The role of oxidative stress in zearalenone-mediated toxicity in Hep G2 cells: Oxidative DNA damage, gluthatione depletion and stress proteins induction. Toxicology, 2007, 232, 294-302.	4.2	164
100	Anticancer effect of a new benzophenanthridine isolated from Zanthoxylum madagascariense (Rutaceline). In Vivo, 2007, 21, 417-22.	1.3	12
101	Phenazine 5,10-Dioxide Derivatives as Hypoxic Selective Cytotoxins: Part II. Structure-Activity Relationship Studies. Medicinal Chemistry, 2006, 2, 511-521.	1.5	18
102	Design andÂevaluation of"3 + 1―mixed ligand oxorhenium andÂoxotechnetium complexes bearing aÂnitroaromatic group with potential application inÂnuclear medicine oncology. European Journal of Medicinal Chemistry, 2006, 41, 1144-1152.	5.5	27
103	Indazole N-oxide derivatives as antiprotozoal agents: Synthesis, biological evaluation and mechanism of action studies. Bioorganic and Medicinal Chemistry, 2006, 14, 3467-3480.	3.0	78
104	Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide derivatives. Journal of Inorganic Biochemistry, 2006, 100, 1358-1367.	3.5	22
105	Oxidative DNA damage induced by Ochratoxin A in the HK-2 human kidney cell line: evidence of the relationship with cytotoxicity. Mutagenesis, 2006, 22, 35-42.	2.6	95
106	Vanadium(V) complexes with salicylaldehyde semicarbazone derivatives bearing in vitro anti-tumor activity toward kidney tumor cells (TK-10): crystal structure of [VVO2(5-bromosalicylaldehyde) Tj ETQq0 0 0 rgB ⁻	ī /@værlock	₹ 1 Ω7 f 50 13
107	Synthesis and biological properties of new 5-nitroindazole derivatives. Bioorganic and Medicinal Chemistry, 2005, 13, 3197-3207.	3.0	63

Study on ochratoxin A in cereal-derived products from Spain. Food Chemistry, 2005, 92, 459-464.

7

#	Article	IF	CITATIONS
109	Novel Cu(II) quinoxaline N1,N4-dioxide complexes as selective hypoxic cytotoxins. European Journal of Medicinal Chemistry, 2005, 40, 473-480.	5.5	58
110	Occurrence of ochratoxin A in cocoa beans: Effect of shelling. Food Additives and Contaminants, 2005, 22, 590-596.	2.0	57
111	Influence of roasting and brew preparation on the ochratoxin A content in coffee infusion. Food Additives and Contaminants, 2005, 22, 463-471.	2.0	60
112	Selective Toxicity of a Quinoxaline 1,4-Di-N-oxide Derivative in Human Tumour Cell Lines. Arzneimittelforschung, 2005, 55, 177-182.	0.4	2
113	DNA damage induced by a quinoxaline 1,4-di-N-oxide derivative (hypoxic selective agent) in Caco-2 cells evaluated by the comet assay. Mutagenesis, 2005, 20, 165-171.	2.6	20
114	Alterations induced in vitro by ochratoxin a in rat lymphoid cells. Human and Experimental Toxicology, 2005, 24, 459-466.	2.2	17
115	Phenazine 5,10-Dioxide Derivatives as Hypoxic Selective Cytotoxins. Journal of Medicinal Chemistry, 2005, 48, 21-23.	6.4	52
116	1, 2, 4-TriazineN-oxide Derivatives: Studies as Potential Hypoxic Cytotoxins. Part II Archiv Der Pharmazie, 2004, 337, 247-258.	4.1	15
117	Determination of ochratoxin A in wine using liquid-phase microextraction combined with liquid chromatography with fluorescence detection. Journal of Chromatography A, 2004, 1025, 163-168.	3.7	100
118	Ruthenium (II) nitrofurylsemicarbazone complexes: new DNA binding agents. European Journal of Medicinal Chemistry, 2004, 39, 377-382.	5.5	32
119	Validation of a high-performance liquid chromatography analytical method for ochratoxin A quantification in cocoa beans. Food Additives and Contaminants, 2004, 21, 1096-1106.	2.0	38
120	Immunotoxic effects of Ochratoxin A in wistar rats after oral administration. Food and Chemical Toxicology, 2004, 42, 825-834.	3.6	83
121	Modulation of mutagenic activity in meat samples after deep-frying in vegetable oils. Mutagenesis, 2002, 17, 63-66.	2.6	14
122	Contribution to the study of ochratoxin A in Spanish wines. Food Additives and Contaminants, 2002, 19, 1058-1064.	2.0	77
123	Induction of micronuclei in V79 cells after combined treatments with heterocyclic aromatic amines. Food and Chemical Toxicology, 2002, 40, 1463-1467.	3.6	14
124	1,2,5-Oxadiazole N-oxide derivatives as potential anti-cancer agents: synthesis and biological evaluation. Part IV. European Journal of Medicinal Chemistry, 2001, 36, 771-782.	5.5	59
125	Determination of ochratoxin A in pig liver-derived pa?te´s by high-performance liquid chromatography. Food Additives and Contaminants, 2001, 18, 559-563.	2.0	14
126	Synthesis and Biological Evaluation of 1,2,5-OxadiazoleN-Oxide Derivatives as Potential Hypoxic Cytotoxins and DNA-Binders. Archiv Der Pharmazie, 2000, 333, 387-393.	4.1	17

#	Article	IF	CITATIONS
127	New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents. European Journal of Medicinal Chemistry, 2000, 35, 21-30.	5.5	60
128	Nonclonal Chromosomal Aberrations Induced by Anti-Tumoral Regimens in Childhood Cancer. Cancer Genetics and Cytogenetics, 2000, 121, 78-85.	1.0	12
129	Study on the Decomposition Products of Thiadiazinthione and their Anticancer Properties. Arzneimittelforschung, 2000, 50, 854-857.	0.4	7
130	Synthesis and Biological Evaluation of 1,2,5-Oxadiazole N-Oxide Derivatives as Potential Hypoxic Cytotoxins and DNA-Binders. Archiv Der Pharmazie, 2000, 333, 387-393.	4.1	0
131	New Quinoxaline 1,4-Di-N-oxides for Treatment of Tuberculosis. Arzneimittelforschung, 1999, 49, 55-59.	0.4	18
132	A high-performance liquid-chromatographic method for the determination of ochratoxin a in human plasma. Chromatographia, 1999, 50, 457-460.	1.3	16
133	Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. European Journal of Cancer, 1999, 35, 320-324.	2.8	41
134	Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitriles. Il Farmaco, 1998, 53, 570-573.	0.9	27
135	Exposure to Ochratoxin a in Europe: Comparison with a Region of Northern Spain. Toxin Reviews, 1998, 17, 479-491.	1.5	36
136	Synthesis and biological evaluation of 1,2,5-oxadiazole N-oxide derivatives as hypoxia-selective cytotoxins. Die Pharmazie, 1998, 53, 758-64.	0.5	15
137	DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. British Journal of Cancer, 1997, 76, 923-929.	6.4	98
138	Screening of Panamanian Medicinal Plants for Brine Shrimp Toxicity, Crown Gall Tumor Inhibition, Cytotoxicity and DNA Intercalation. International Journal of Pharmacognosy, 1996, 34, 19-27.	0.2	57
139	4-Cyano-2-oxo-1,2,4-oxadiazolo[2,3-a]quinoxaline 5-N-oxides. New synthetic method and reaction with alcohols. Potential cytotoxic activity. Journal of Heterocyclic Chemistry, 1996, 33, 1671-1677.	2.6	16
140	New hypoxiaâ€selective cytotoxines derived from quinoxaline 1,4â€dioxides. Journal of Heterocyclic Chemistry, 1995, 32, 1213-1217.	2.6	30
141	Hypoxia-Selective Agents Derived from Quinoxaline 1,4-Di-N-oxides. Journal of Medicinal Chemistry, 1995, 38, 1786-1792.	6.4	127
142	Hypoxia-Selective Agents Derived from 2-Quinoxalinecarbonitrile 1,4-Di-N-oxides. 2. Journal of Medicinal Chemistry, 1995, 38, 4488-4494.	6.4	117
143	Hypoxia-selective antitumor agents derived from 1,9-diazaanthracene. European Journal of Medicinal Chemistry, 1994, 29, 441-445.	5.5	6
144	3â€Aminoâ€2â€quinoxalinecarbonitrile. New fused quinoxalines with potential cytotoxic activity. Journal of Heterocyclic Chemistry, 1994, 31, 1135-1139.	2.6	30

#	Article	IF	CITATIONS
145	Bacterial mutagenic evaluation of a series of 4′ substituted derivatives of 3-benzylidenamino-5H-1, 2, 3-triazin[5, 4b]indol-4-one. Mutagenesis, 1992, 7, 31-35.	2.6	1
146	Influence of the triazine ring on the mutagenicity of triazinoindoles and some congeners. Mutagenesis, 1992, 7, 37-40.	2.6	6
147	Quantitative structure-mutagenic activity relationships of triazino indole derivatives. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1992, 268, 1-9.	1.0	4
148	Mutagenic evaluation of some triazino indoles using the Salmonella/mammalian microsome assay. Mutagenesis, 1990, 5, 307-312.	2.6	4